Thyrocare Technologies Limited reports revenue of INR 240.02 Cr in Q1FY27 with a growth of 24% YoY
Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended June 30, 2027.
From Routine to Remarkable: The Next Frontier of Diagnostics
Thyrocare expanded into Specialty Diagnostics, marking the next phase of its growth journey and the next frontier of diagnostics. The Company commenced this journey with Allergy and Genomics and progressively expanded its specialty test portfolio, with a focus on building clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times
Key Financial Highlights for Q1FY27
Consolidated revenue registered a 24% year-on-year growth, driven primarily by a 26% increase in the Pathology segment
In the Pathology business, franchise revenue grew by 27% year-on-year, while partnership revenue recorded 26% year-on-year growth
Thyrocare, India’s largest diagnostic test volume processor, processed 55.2 million tests in Q1FY27, marking a strong 28% year-on-year growth and reinforcing its volume leadership position in the industry
Consolidated EBITDA grew by 34% year-on-year to Rs 77.27 Cr, and Profit After Tax (PAT) grew by 34% year-on-year to Rs 51.33 Cr
Sustained Six Sigma quality standards, reducing complaints per million tests to 3.1 (down 24% YoY) with ATAT at 3.37 hours - India's first diagnostic chain to hit this benchmark
Thyrocare Reports Robust Q1FY27 Results – Revenue Up 24%, PAT Up 34%
The company delivered a robust performance in Q1FY27 with consolidated revenue of ₹240.02 crore, registering a strong 24% year-on-year growth, led by continued momentum in the Pathology segment which grew 26% YoY. EBITDA rose by 34% YoY to ₹77.27 crore. Profit After Tax surged 34% YoY to ₹51.33 crore, underscoring the company’s focus on profitable growth.
India’s largest diagnostic test volume processor further strengthened its volume leadership position during the quarter, processing 55.2 million tests up 28% year-on-year. The Pathology business maintained strong traction with franchise revenue up 27% and partnership revenue up 26% year-on-year.
Thyrocare's unwavering commitment to quality delivered Six Sigma excellence by reducing complaints to 3.1 per million (down 24% YoY) with ATAT at 3.37 hours from sample receipt, positioning the company as India's first diagnostic chain to attain this benchmark.
Thyrocare expanded into Specialty Diagnostics, marking the next phase of its growth journey and the next frontier of diagnostics. The Company commenced this journey with Allergy and Genomics and progressively expanded its specialty test portfolio, with a focus on building clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times
Senior management remarks:
“Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India”
Got a story that Healthcare Executive should dig into? Shoot it over to arunima.rajan@hosmac.com—no PR fluff, just solid leads.